Skip to main content
NCBI home page
The EMBO Journal logoLink to The EMBO Journal
. 1991 Dec;10(13):4041–4048. doi: 10.1002/j.1460-2075.1991.tb04980.x

A mutation in a mild form of galactosialidosis impairs dimerization of the protective protein and renders it unstable.

X Y Zhou 1, N J Galjart 1, R Willemsen 1, N Gillemans 1, H Galjaard 1, A d'Azzo 1
PMCID: PMC453152  PMID: 1756715

Abstract

The lysosomal disorder galactosialidosis is caused by deficiency of the protective protein in the absence of which the activities of the enzymes beta-galactosidase and neuraminidase are reduced. Aside from its protective function towards the two glycosidases, this protein has cathepsin A-like activity. A point mutation in the protective protein gene, resulting in the substitution of Phe412 with Val in the gene product, was identified in two unrelated patients with the late infantile form of the disease. Expression in COS-1 cells of a protective protein cDNA with the base substitution resulted in the synthesis of a mutant protein that lacks cathepsin A-like activity. The newly made mutant precursor was shown to be partially retained in the endoplasmic reticulum. Only a fraction is transported to the lysosomes where it is degraded soon after proteolytic processing into the mature two-chain form. Since the mutant precursor, contrary to the wild type protein, does not form homodimers, the dimerization process might be a condition for the proper targeting and stable conformation of the protective protein. These results clarify the mechanism underlying the combined deficiency in these patients, and give new insight into the structure-function relationship of the wild type protein.

Full text

PDF
4041

Images in this article

4042Image
on p.4042
4043Image
on p.4043
4044Image
on p.4044
4045Image
on p.4045
4046Image
on p.4046

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andria G., Del Giudice E., Reuser A. J. Atypical expression of beta-galactosidase deficiency in a child with Hurler-like features but without neurological abnormalities. Clin Genet. 1978 Jul;14(1):16–23. doi: 10.1111/j.1399-0004.1978.tb02055.x. [DOI] [PubMed] [Google Scholar]
  2. Auffray C., Rougeon F. Purification of mouse immunoglobulin heavy-chain messenger RNAs from total myeloma tumor RNA. Eur J Biochem. 1980 Jun;107(2):303–314. doi: 10.1111/j.1432-1033.1980.tb06030.x. [DOI] [PubMed] [Google Scholar]
  3. Chitayat D., Applegarth D. A., Lewis J., Dimmick J. E., McCormick A. Q., Hall J. G. Juvenile galactosialidosis in a white male: a new variant. Am J Med Genet. 1988 Dec;31(4):887–901. doi: 10.1002/ajmg.1320310423. [DOI] [PubMed] [Google Scholar]
  4. D'Azzo A., Hoogeveen A., Reuser A. J., Robinson D., Galjaard H. Molecular defect in combined beta-galactosidase and neuraminidase deficiency in man. Proc Natl Acad Sci U S A. 1982 Aug;79(15):4535–4539. doi: 10.1073/pnas.79.15.4535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Frisch A., Neufeld E. F. Limited proteolysis of the beta-hexosaminidase precursor in a cell-free system. J Biol Chem. 1981 Aug 10;256(15):8242–8246. [PubMed] [Google Scholar]
  6. Galjart N. J., Gillemans N., Harris A., van der Horst G. T., Verheijen F. W., Galjaard H., d'Azzo A. Expression of cDNA encoding the human "protective protein" associated with lysosomal beta-galactosidase and neuraminidase: homology to yeast proteases. Cell. 1988 Sep 9;54(6):755–764. doi: 10.1016/s0092-8674(88)90999-3. [DOI] [PubMed] [Google Scholar]
  7. Galjart N. J., Gillemans N., Meijer D., d'Azzo A. Mouse "protective protein". cDNA cloning, sequence comparison, and expression. J Biol Chem. 1990 Mar 15;265(8):4678–4684. [PubMed] [Google Scholar]
  8. Galjart N. J., Morreau H., Willemsen R., Gillemans N., Bonten E. J., d'Azzo A. Human lysosomal protective protein has cathepsin A-like activity distinct from its protective function. J Biol Chem. 1991 Aug 5;266(22):14754–14762. [PubMed] [Google Scholar]
  9. Gluzman Y. SV40-transformed simian cells support the replication of early SV40 mutants. Cell. 1981 Jan;23(1):175–182. doi: 10.1016/0092-8674(81)90282-8. [DOI] [PubMed] [Google Scholar]
  10. Hermans A., Gow J., Selleri L., von Lindern M., Hagemeijer A., Wiedemann L. M., Grosveld G. bcr-abl oncogene activation in Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia. 1988 Oct;2(10):628–633. [PubMed] [Google Scholar]
  11. Higuchi R., Krummel B., Saiki R. K. A general method of in vitro preparation and specific mutagenesis of DNA fragments: study of protein and DNA interactions. Nucleic Acids Res. 1988 Aug 11;16(15):7351–7367. doi: 10.1093/nar/16.15.7351. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hoogeveen A. T., Verheijen F. W., Galjaard H. The relation between human lysosomal beta-galactosidase and its protective protein. J Biol Chem. 1983 Oct 25;258(20):12143–12146. [PubMed] [Google Scholar]
  13. Hurtley S. M., Helenius A. Protein oligomerization in the endoplasmic reticulum. Annu Rev Cell Biol. 1989;5:277–307. doi: 10.1146/annurev.cb.05.110189.001425. [DOI] [PubMed] [Google Scholar]
  14. Jackman H. L., Tan F. L., Tamei H., Beurling-Harbury C., Li X. Y., Skidgel R. A., Erdös E. G. A peptidase in human platelets that deamidates tachykinins. Probable identity with the lysosomal "protective protein". J Biol Chem. 1990 Jul 5;265(19):11265–11272. [PubMed] [Google Scholar]
  15. Kadowaki T., Kadowaki H., Taylor S. I. A nonsense mutation causing decreased levels of insulin receptor mRNA: detection by a simplified technique for direct sequencing of genomic DNA amplified by the polymerase chain reaction. Proc Natl Acad Sci U S A. 1990 Jan;87(2):658–662. doi: 10.1073/pnas.87.2.658. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Kase R., Itoh K., Takiyama N., Oshima A., Sakuraba H., Suzuki Y. Galactosialidosis: simultaneous deficiency of esterase, carboxy-terminal deamidase and acid carboxypeptidase activities. Biochem Biophys Res Commun. 1990 Nov 15;172(3):1175–1179. doi: 10.1016/0006-291x(90)91572-a. [DOI] [PubMed] [Google Scholar]
  17. Loonen M. C., Reuser A. J., Visser P., Arts W. F. Combined sialidase (neuraminidase) and beta-galactosidase deficiency. Clinical, morphological and enzymological observations in a patient. Clin Genet. 1984 Aug;26(2):139–149. doi: 10.1111/j.1399-0004.1984.tb00804.x. [DOI] [PubMed] [Google Scholar]
  18. Murphy G., Kavanagh T. Speeding-up the sequencing of double-stranded DNA. Nucleic Acids Res. 1988 Jun 10;16(11):5198–5198. doi: 10.1093/nar/16.11.5198. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Navon R., Proia R. L. Tay-Sachs disease in Moroccan Jews: deletion of a phenylalanine in the alpha-subunit of beta-hexosaminidase. Am J Hum Genet. 1991 Feb;48(2):412–419. [PMC free article] [PubMed] [Google Scholar]
  20. Navon R., Proia R. L. Tay-Sachs disease in Moroccan Jews: deletion of a phenylalanine in the alpha-subunit of beta-hexosaminidase. Am J Hum Genet. 1991 Feb;48(2):412–419. [PMC free article] [PubMed] [Google Scholar]
  21. Neufeld E. F. Natural history and inherited disorders of a lysosomal enzyme, beta-hexosaminidase. J Biol Chem. 1989 Jul 5;264(19):10927–10930. [PubMed] [Google Scholar]
  22. Okada S., Kato T., Miura S., Yabuuchi H., Nishigaki M., Kobata A., Chiyo H., Furuyama J. I. Hypersialyloligosacchariduria in mucolipidoses: a method for diagnosis. Clin Chim Acta. 1978 Jun;86(2):159–167. doi: 10.1016/0009-8981(78)90129-8. [DOI] [PubMed] [Google Scholar]
  23. Okayama H., Berg P. A cDNA cloning vector that permits expression of cDNA inserts in mammalian cells. Mol Cell Biol. 1983 Feb;3(2):280–289. doi: 10.1128/mcb.3.2.280. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Palmeri S., Hoogeveen A. T., Verheijen F. W., Galjaard H. Galactosialidosis: molecular heterogeneity among distinct clinical phenotypes. Am J Hum Genet. 1986 Feb;38(2):137–148. [PMC free article] [PubMed] [Google Scholar]
  25. Paw B. H., Wood L. C., Neufeld E. F. A third mutation at the CpG dinucleotide of codon 504 and a silent mutation at codon 506 of the HEX A gene. Am J Hum Genet. 1991 Jun;48(6):1139–1146. [PMC free article] [PubMed] [Google Scholar]
  26. Pinsky L., Miller J., Shanfield B., Watters G., Wolfe L. S. GM1 gangliosidosis in skin fibroblast culture: enzymatic differences between types 1 and 2 and observations on a third variant. Am J Hum Genet. 1974 Sep;26(5):563–577. [PMC free article] [PubMed] [Google Scholar]
  27. Proia R. L., d'Azzo A., Neufeld E. F. Association of alpha- and beta-subunits during the biosynthesis of beta-hexosaminidase in cultured human fibroblasts. J Biol Chem. 1984 Mar 10;259(5):3350–3354. [PubMed] [Google Scholar]
  28. Roth M. Fluorescence reaction for amino acids. Anal Chem. 1971 Jun;43(7):880–882. doi: 10.1021/ac60302a020. [DOI] [PubMed] [Google Scholar]
  29. Saiki R. K., Scharf S., Faloona F., Mullis K. B., Horn G. T., Erlich H. A., Arnheim N. Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science. 1985 Dec 20;230(4732):1350–1354. doi: 10.1126/science.2999980. [DOI] [PubMed] [Google Scholar]
  30. Sewell A. C., Pontz B. F., Weitzel D., Humburg C. Clinical heterogeneity in infantile galactosialidosis. Eur J Pediatr. 1987 Sep;146(5):528–531. doi: 10.1007/BF00441610. [DOI] [PubMed] [Google Scholar]
  31. Simmons W. H., Walter R. Carboxamidopeptidase: purification and characterization of a neurohypophyseal hormone inactivating peptidase from toad skin. Biochemistry. 1980 Jan 8;19(1):39–48. doi: 10.1021/bi00542a007. [DOI] [PubMed] [Google Scholar]
  32. Smith P. K., Krohn R. I., Hermanson G. T., Mallia A. K., Gartner F. H., Provenzano M. D., Fujimoto E. K., Goeke N. M., Olson B. J., Klenk D. C. Measurement of protein using bicinchoninic acid. Anal Biochem. 1985 Oct;150(1):76–85. doi: 10.1016/0003-2697(85)90442-7. [DOI] [PubMed] [Google Scholar]
  33. Strisciuglio P., Parenti G., Giudice C., Lijoi S., Hoogeveen A. T., d'Azzo A. The presence of a reduced amount of 32-kd "protective" protein is a distinct biochemical finding in late infantile galactosialidosis. Hum Genet. 1988 Nov;80(3):304–306. doi: 10.1007/BF01790104. [DOI] [PubMed] [Google Scholar]
  34. Strisciuglio P., Sly W. S., Dodson W. E., McAlister W. H., Martin T. C. Combined deficiency of beta-galactosidase and neuraminidase: natural history of the disease in the first 18 years of an American patient with late infantile onset form. Am J Med Genet. 1990 Dec;37(4):573–577. doi: 10.1002/ajmg.1320370431. [DOI] [PubMed] [Google Scholar]
  35. Taylor S., Tappel A. L. Lysosomal peptidase measurement by sensitive fluorometric amino acid analysis. Anal Biochem. 1973 Nov;56(1):140–148. doi: 10.1016/0003-2697(73)90178-4. [DOI] [PubMed] [Google Scholar]
  36. Tranchemontagne J., Michaud L., Potier M. Deficient lysosomal carboxypeptidase activity in galactosialidosis. Biochem Biophys Res Commun. 1990 Apr 16;168(1):22–29. doi: 10.1016/0006-291x(90)91669-j. [DOI] [PubMed] [Google Scholar]
  37. Van Pelt J., Van Kuik J. A., Kamerling J. P., Vliegenthart J. F., Van Diggelen O. P., Galjaard H. Storage of sialic acid-containing carbohydrates in the placenta of a human galactosialidosis fetus. Isolation and structural characterization of 16 sialyloligosaccharides. Eur J Biochem. 1988 Nov 1;177(2):327–338. doi: 10.1111/j.1432-1033.1988.tb14380.x. [DOI] [PubMed] [Google Scholar]
  38. Verheijen F., Brossmer R., Galjaard H. Purification of acid beta-galactosidase and acid neuraminidase from bovine testis: evidence for an enzyme complex. Biochem Biophys Res Commun. 1982 Sep 30;108(2):868–875. doi: 10.1016/0006-291x(82)90911-1. [DOI] [PubMed] [Google Scholar]
  39. Wenger D. A., Tarby T. J., Wharton C. Macular cherry-red spots and myoclonus with dementia: coexistent neuraminidase and beta-galactosidase deficiencies. Biochem Biophys Res Commun. 1978 May 30;82(2):589–595. doi: 10.1016/0006-291x(78)90915-4. [DOI] [PubMed] [Google Scholar]
  40. Willemsen R., Hoogeveen A. T., Sips H. J., van Dongen J. M., Galjaard H. Immunoelectron microscopical localization of lysosomal beta-galactosidase and its precursor forms in normal and mutant human fibroblasts. Eur J Cell Biol. 1986 Mar;40(1):9–15. [PubMed] [Google Scholar]
  41. van Pelt J., Hård K., Kamerling J. P., Vliegenthart J. F., Reuser A. J., Galjaard H. Isolation and structural characterization of twenty-one sialyloligosaccharides from galactosialidosis urine. An intact N,N'-diacetylchitobiose unit at the reducing end of a diantennary structure. Biol Chem Hoppe Seyler. 1989 Mar;370(3):191–203. doi: 10.1515/bchm3.1989.370.1.191. [DOI] [PubMed] [Google Scholar]
  42. van Pelt J., Kamerling J. P., Vliegenthart J. F., Hoogeveen A. T., Galjaard H. A comparative study of the accumulated sialic acid-containing oligosaccharides from cultured human galactosialidosis and sialidosis fibroblasts. Clin Chim Acta. 1988 Jun 15;174(3):325–335. doi: 10.1016/0009-8981(88)90059-9. [DOI] [PubMed] [Google Scholar]
  43. van der Horst G. T., Galjart N. J., d'Azzo A., Galjaard H., Verheijen F. W. Identification and in vitro reconstitution of lysosomal neuraminidase from human placenta. J Biol Chem. 1989 Jan 15;264(2):1317–1322. [PubMed] [Google Scholar]

Articles from The EMBO Journal are provided here courtesy of Nature Publishing Group

RESOURCES